Background and objective Epidermal growth factor receptor tyrosine kinase inhinitors (EGFR-TKIs) inhibit tumor growth by affecting signal transduction, and are well tolerated. hTe aims of this study was to observe the effect of erlotinib in patients with squamous cell lung cancer.Methods hTe 34 patients with squamous cell lung cancer treated with er-lotinib 150 mg orally once daily until disease progression or intolerable adverse reactions.Results hTe 7 patients were treated with erlotinib as ifrst-line treatment, 6 patients as maintenance therapy (1 case withdrawal of severe toxicity), 9 patients second-line treatment, 5 patients as third-line and 7 patients as further-line therapy. 11 patients died. hTe median progression-free sur-vival (PFS) was 3.5 months, ranging from 1 month to 55 months (the patient withdrawal of severe toxicity was not included). Conclusion Erlotinib was effective for patients with squamous cell lung cancer who can not tolerate chemotherapy or refused chemotherapy and with unknown EGFR status. Adverse reactions were tolerable.%背景与目的表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhinitor, EGFR-TKI）通过影响肿瘤的信号传导来抑制肿瘤发展，它具有良好的安全性。本研究旨在观察厄洛替尼治疗肺鳞癌患者的基本情况及生存时间。方法对34例使用厄洛替尼靶向治疗的肺鳞癌患者，给予厄洛替尼150 mg每日1次口服直至病情进展或因不良反应不能耐受为止。结果截至2016年6月13日，34例患者中一线治疗患者7例，维持治疗患者6例（其中1例因严重毒性反应停药），二线治疗患者9例（其中1例患者后续再次使用厄洛替尼），三线治疗患者5例，三线以上治疗患者7例（其中1例患者为2次使用厄洛替尼）；确认死亡患者11例。除去1例严重不良反应的患者，口服厄洛替尼后最短疾病无进展生存时间（progression-free survival, PFS）为1个月，最长PFS为55个月，中位PFS为3.5个月。结论对于一部分晚期不能耐受化疗或拒绝化疗，并且基因状况不明的肺鳞癌患者来说，厄洛替尼有一定疗效，绝大部分患者不良反应可耐受。
展开▼
